Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Trojan

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Aktuelle Urologie|January 30, 2009
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]C Bolenz, L Trojan, P Honeck, et al.
EJNMMI Research|November 19, 2015
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyB Meller, F Bremmer, C O Sahlmann, et al.
Der Urologe. Ausg. A|July 12, 2007
[Complications and side effects of low dose rate brachytherapy for the treatment of prostate cancer: data on a 13 year follow-up study from Mannheim]L Trojan, K Harrer, J Schäfer, et al.
The Prostate|September 11, 2015
Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomographyS Hijazi, B Meller, C Leitsmann, et al.
Der Radiologe|June 27, 2003
[Detection of prostate carcinomas with T1-weighted dynamic contrast-enhanced MRI. Value of two-compartment model]F Kiessling, M Lichy, R Grobholz, et al.
Hepato-Gastroenterology|July 21, 2001
IGF-I triple helix strategy in hepatoma treatmentL C Upegui-Gonzalez, A Ly, M Sierzega, et al.
Der Urologe. Ausg. A|October 6, 2010
[Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens]M May, H-M Fritsche, S Brookman-May, et al.
World Journal of Urology|June 6, 2013
Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validationM Gierth, H M Fritsche, H Buchner, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 31, 2012
External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladderP Nuhn, M May, H-M Fritsche, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2013
Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networksA Buchner, M May, M Burger, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Aktuelle Urologie|January 30, 2009
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]C Bolenz, L Trojan, P Honeck, et al.
EJNMMI Research|November 19, 2015
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyB Meller, F Bremmer, C O Sahlmann, et al.
Der Urologe. Ausg. A|July 12, 2007
[Complications and side effects of low dose rate brachytherapy for the treatment of prostate cancer: data on a 13 year follow-up study from Mannheim]L Trojan, K Harrer, J Schäfer, et al.
The Prostate|September 11, 2015
Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomographyS Hijazi, B Meller, C Leitsmann, et al.
Der Radiologe|June 27, 2003
[Detection of prostate carcinomas with T1-weighted dynamic contrast-enhanced MRI. Value of two-compartment model]F Kiessling, M Lichy, R Grobholz, et al.
Hepato-Gastroenterology|July 21, 2001
IGF-I triple helix strategy in hepatoma treatmentL C Upegui-Gonzalez, A Ly, M Sierzega, et al.
Der Urologe. Ausg. A|October 6, 2010
[Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens]M May, H-M Fritsche, S Brookman-May, et al.
World Journal of Urology|June 6, 2013
Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validationM Gierth, H M Fritsche, H Buchner, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 31, 2012
External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladderP Nuhn, M May, H-M Fritsche, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2013
Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networksA Buchner, M May, M Burger, et al.
Pageof 4